MedTrace Logo

Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3

NCT05264584 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-03-25

No results posted yet for this study

Summary

This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.

Conditions

  • Chronic Kidney Disease stage3
  • Contrast-induced Nephropathy

Interventions

DRUG

Isotonic saline

All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.

DRUG

N-acetyl cysteine

all the patients will receive 600 mg orally twice daily ,on the day before and the day of exposure to contrast or a single periprocedural dose (within 4 hours of contrast exposure) 1200 mg .

DRUG

Febuxostat 80 MG

All patients will receive a continuous intravenous infusion of isotonic saline at a rate of 0.5 mL/kg/h for at least 2 to 12 hours before the procedure and continued to receive it 6 to 24 hours afterward.

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Rania Saad, Bachelor · Faculty of medicine Ain shams university

  • Iman Sarhan, PhD · Faculty of medicine Ain Shams university

  • Nahla Teama, PhD · Faculty of medicine Ain Shams university

  • Yasser Alaa, PhD · Faculty of medicine Ain Shams university

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2021-09-01
Completion
2022-02-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05264584 on ClinicalTrials.gov